Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.14 USD
Change Today +0.03 / 2.70%
Volume 226.3K
ATHX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

athersys inc (ATHX) Snapshot

Open
$1.11
Previous Close
$1.11
Day High
$1.16
Day Low
$1.11
52 Week High
03/23/15 - $3.43
52 Week Low
04/17/15 - $0.90
Market Cap
94.8M
Average Volume 10 Days
253.9K
EPS TTM
$-0.32
Shares Outstanding
83.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATHERSYS INC (ATHX)

Related News

No related news articles were found.

athersys inc (ATHX) Related Businessweek News

No Related Businessweek News Found

athersys inc (ATHX) Details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has license agreement with Chugai Pharmaceutical Co., Ltd. to develop MultiStem cell therapy for ischemic stroke in Japan, as well as collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

57 Employees
Last Reported Date: 03/12/15
Founded in 1995

athersys inc (ATHX) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $599.8K
President, Chief Operating Officer and Secret...
Total Annual Compensation: $464.5K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $462.0K
Principal Financial Officer and Vice Presiden...
Total Annual Compensation: $283.3K
Executive Vice President of Regenerative Medi...
Total Annual Compensation: $381.6K
Compensation as of Fiscal Year 2014.

athersys inc (ATHX) Key Developments

Athersys, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2015

Athersys, Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2015. For the quarter, the company reported total revenues of $216,000 compared to $388,000 a year ago, reflecting a decrease in grant revenues. Loss from operations was of $7,034,000 compared to $7,286,000, a year ago. Net loss and comprehensive loss was $1,035,000 or $0.05 per diluted share compared to net income and comprehensive net income of $675,000 or $0.04 per diluted share a year ago. Cash used in operating activities during the second quarter of 2015 was $5.8 million compared to $6.1 million cash used in the second quarter of 2014. The increase in net loss reflects the $200,000 reduction in loss from operations is offset by the $1.9 million increase in noncash expense from warrant liability valuation.

Athersys, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Athersys, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2015

Athersys, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Athersys, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATHX:US $1.14 USD +0.03

ATHX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $8.45 USD 0.00
Cytori Therapeutics Inc $0.30 USD -0.0268
IntelliCell BioSciences Inc $0.0001 USD 0.00
Pluristem Therapeutics Inc $1.95 USD 0.00
StemCells Inc $0.39 USD +0.0055
View Industry Companies
 

Industry Analysis

ATHX

Industry Average

Valuation ATHX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 62.3x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATHERSYS INC, please visit www.athersys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.